The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
美国食品药品管理局已批准Can-Fite Biopharma正在进行的2B期研究的Namodenoson治疗代谢功能障碍相关脂肪肝炎（也称为非酒精性脂肪性肝炎）的新药研究许可
The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
美国食品药品管理局已批准Can-Fite Biopharma正在进行的2B期研究的Namodenoson治疗代谢功能障碍相关脂肪肝炎（也称为非酒精性脂肪性肝炎）的新药研究许可
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。